1 / 13

Joensuu H, Eriksson M, Sundby Hall K, et al. JAMA. 2012;307(12):1265–1272

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor A Randomized Trial. Joensuu H, Eriksson M, Sundby Hall K, et al. JAMA. 2012;307(12):1265–1272. SSGXVIII/AIO: Design. An open-label Phase III study. N=400. Imatinib for 12 months. Follow-up. Random

mick
Télécharger la présentation

Joensuu H, Eriksson M, Sundby Hall K, et al. JAMA. 2012;307(12):1265–1272

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal TumorA Randomized Trial Joensuu H, Eriksson M, Sundby Hall K, et al. JAMA. 2012;307(12):1265–1272

  2. SSGXVIII/AIO: Design An open-label Phase III study N=400 Imatinib for 12 months Follow-up Random Assignment 1:1 Imatinib for 36 months Follow-up Stratification: 1) R0 resection, no tumor rupture 2) R1 resection or tumor rupture Joensuu H et al. JAMA 2012;307(12):1265–1272

  3. SSGXVIII/AIO: Methods Endpoints1 Treatment1 Imatinib • 400 mg/d (12 vs 36 months) Primary • RFS Secondary • Treatment safety • OS • GIST-specific survival Key inclusion criteria1 • Histologically confirmed GIST, KIT-positive • High risk of recurrence according to the modified consensus criteria2,3 • Tumor size >10 cm or • Tumor mitosis count >10/50 HPF or • Size >5 cm and mitosis count >5/50 HPF or • Tumor rupture before surgery or at surgery • HPF, high-power field of the microscope. • Joensuu H et al. JAMA 2012;307(12):1265–1272 • Fletcher CD et al. Hum Pathol 2002;33:459–465 • Joensuu H. Hum Pathol2008;39:1411−1419.

  4. SSGXVIII/AIO: Patient Disposition *Three patients who withdrew consent were excluded Joensuu H et al. JAMA 2012;307(12):1265–1272

  5. SSGXVIII/AIO: Baseline Characteristics (ITT Population) *Per 50 high power fields **Available for 366 (92%) out of the 397 tumors Joensuu H et al. JAMA 2012;307(12):1265–1272

  6. SSGXVIII/AIO: Baseline Characteristics (ITT Population) Joensuu H et al. JAMA 2012;307(12):1265–1272

  7. SSGXVIII/AIO: RFS Events and Deaths (ITT Population) Median follow-up time: 54 months (from the date of randomization to the date of data cut-off, Dec 31, 2010) Joensuu H et al. JAMA 2012;307(12):1265–1272

  8. SSGXVIII/AIO: Recurrence-Free Survival (ITT Population) 36 Months of imatinib 3-year survival : 36 months, 86.6% 12 months, 60.1% 5-year survival : 36 months, 65.6% 12 months, 47.9% Percentage 12 Months of imatinib HR, 0.46 (95% CI, 0.32-0.65) Log-rank P<.001 Time Since Randomisation, y No. of patients Joensuu H et al. JAMA 2012;307(12):1265–1272

  9. SSGXVIII/AIO: RFS in Efficacy Population 36 Months of imatinib 3-year survival : 36 months, 88.1% 12 months, 62.1% 5-year survival : 36 months, 67.4% 12 months, 50.3% Percentage 12 Months of imatinib HR, 0.46 (95% CI, 0.31-0.68) Log-rank P<.001 Time Since Randomisation, y No. of patients Excluded: consent withdrawn, no GIST at pathology review, or overt metastases at study entry Joensuu H et al. JAMA 2012;307(12):1265–1272

  10. SSGXVIII/AIO: RFS in Subgroups Favors 36 mo of Imatinib Favors 12 mo of Imatinib 0.1 10 1.0 Joensuu H et al. JAMA 2012;307(12):1265–1272 HR (95% CI)

  11. SSGXVIII/AIO: Overall Survival (ITT Population) 36 Months of imatinib 12 Months of imatinib 3-year survival : 36 months, 96.3% 12 months, 94.0% 5-year survival : 36 months, 92.0% 12 months, 81.7% Percentage HR, 0.45 (95% CI, 0.22-0.89) Log-rank P = .02 Time Since Randomisation, y No. of patients Joensuu H et al. JAMA 2012;307(12):1265–1272

  12. SSGXVIII/AIO: Treatment Safety • Cardiac AEs and second malignancies were low and comparable in both treatment arms Joensuu H et al. JAMA 2012;307(12):1265–1272

  13. SSGXVIII/AIO: Conclusions • Compared with 1 year of treatment, 3 years of adjuvant imatinib significantly improves RFS and OS for patients with GIST who are at a high risk of recurrence after surgery • Adjuvant imatinib is relatively well tolerated; severe adverse events are infrequent • This trial has established 3 years of 400 mg imatinib as the new standard of care for adjuvant treatment of patients with high-risk GIST • Both the US Food and Drug Administration and European commission approved label updates that include 3-year duration for adjuvant treatment of KIT+ GIST patients • The National Comprehensive Cancer Network updated recommendations to include 3 years of adjuvant imatinib therapy as the new standard of care for KIT+ GIST patients Joensuu H et al. JAMA 2012;307(12):1265–1272

More Related